The US Food and Drug Administration has approved a new bispecific antibody for the treatment of non-small cell lung cancer whose tumours have a specific genetic mutation. Rybrevant (amivantamab) was authorised for patients with lung cancers which have an epidermal growth factor receptor (EGFR) exon 20 insertion mutation.
